The Doctor's Seal: Decoding Bonafide's Menopause Market Milestone

NEW YORK, NY – June 16, 2026 – In a significant move within the rapidly expanding women's health sector, Bonafide Health announced that a national survey of 600 gynecologists named several of its products the most recommended in their respective categories for menopause symptom relief. The announcement serves as a powerful validation in a market where consumers are increasingly seeking evidence-backed, non-hormonal solutions. While the press release marks a clear victory for the company, it also illuminates a broader strategic shift in how women's health, particularly during the menopause transition, is being addressed by consumers, clinicians, and corporations alike.

Bonafide, a subsidiary of health and wellness giant Pharmavite, has carved a niche by focusing exclusively on hormone-free and prescription-free options. The survey's findings, particularly the top ranking for its Revaree® vaginal moisturizer and Ristela® supplement for sexual enhancement, provide a coveted 'doctor-recommended' halo that can significantly influence consumer choice in a crowded and often confusing marketplace.

A Stamp of Clinical Approval

The survey, conducted online by market research firm Catapult Insights between April 9-19, 2026, is the foundation of the new claims. According to the results, Revaree® and its extra-strength counterpart, Revaree® Plus, were named the #1 Gynecologist recommended over-the-counter hyaluronic acid insert for vaginal dryness. This is a critical endorsement for a common and often undertreated symptom of menopause. Unlike many supplements, Revaree is an FDA-cleared, Class-II Medical Device, a regulatory status that requires demonstration of substantial equivalence to an existing safe and effective device. This clearance provides a layer of clinical credibility that separates it from products in the less-regulated dietary supplement space.

"Women in menopause are seeking quality solutions to ease their symptoms," said Sonny Stafford, Chief Commercial Officer at Bonafide, in the company's official release. "Being named #1 by leading health authorities validates that Bonafide products are trusted clinical allies, not just symptom relievers."

Other products also gained significant recognition. Ristela®, a plant-based supplement designed to improve sexual response, was named the #1 Gynecologist recommended dietary supplement for orgasm enhancement among those who recommend such a product. Additionally, the survey highlighted positive physician sentiment for Thermella®, for hot flashes, and Clairvee®, a probiotic for vaginal odor. This suite of endorsements allows the company to build a narrative of comprehensive, physician-trusted care for the multifaceted symptoms of perimenopause and menopause.

Beyond Hormones: A Market in Transition

The significance of Bonafide's achievement cannot be understood without examining the deep-seated trends driving the women's health market. For decades, Hormone Replacement Therapy (HRT) was the default medical response to menopause symptoms. However, the landscape shifted dramatically in the early 2000s following the Women's Health Initiative (WHI) study, which linked combined estrogen-progestin therapy to increased risks of breast cancer, stroke, and heart disease. While subsequent analysis has nuanced those findings—showing that risks are highly dependent on a woman's age, health profile, and the timing of therapy—a persistent apprehension remains among millions of women.

This has created a powerful demand for effective non-hormonal alternatives. Bonafide's own market research underscores this shift, with one of its surveys finding that 65% of women would not consider using HRT. Furthermore, many women are not candidates for hormone therapy due to pre-existing conditions like a history of certain cancers or cardiovascular issues. This confluence of patient preference and medical necessity has created a vast, underserved market.

"There is a powerful and growing desire for treatments that align with a 'less is more' philosophy, but that doesn't mean women are willing to compromise on efficacy," commented one independent women's health analyst. "They want options that are backed by science but free from the perceived risks of systemic hormones. A 'doctor-recommended' claim, especially when tied to a specific survey, speaks directly to this desire for trusted, evidence-based alternatives."

Decoding 'Doctor Recommended'

For the discerning consumer, the phrase 'doctor recommended' warrants a closer look. Industry-sponsored surveys are a standard and legitimate tool for substantiating advertising claims. Catapult Insights, the firm behind the research, positions itself as an expert in quantitative claims substantiation with a rigorous methodology. However, it's crucial for consumers to understand the context.

The value of such a claim rests on the survey's design, the representativeness of its sample, and the precise wording of its questions—details not typically available in a public press release. Without access to the full report, it's impossible to analyze the potential for sponsor bias or how competing products were presented to the 600 participating OBGYNs.

Furthermore, it is vital to distinguish between the regulatory status of different products. Revaree's standing as an FDA-cleared medical device places it in a different category than Thermella, Clairvee, and Ristela, which are marketed as dietary supplements. As their own packaging often notes, for these supplements, "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." This doesn't negate their potential benefits or the validity of the physician recommendations, but it highlights a different level of regulatory scrutiny compared to medical devices or prescription drugs. The gynecologist recommendations, therefore, serve as a form of professional consensus that supplements, but does not replace, formal regulatory evaluation.

The Strategic Play for Mainstream Trust

This announcement is more than a marketing win; it's a key move in a larger corporate strategy. As part of Pharmavite—the powerhouse behind Nature Made® vitamins—and ultimately a subsidiary of Japan's Otsuka Pharmaceutical Co., Ltd., Bonafide has the backing to scale its operations and brand message. The company has already been expanding its retail footprint into major chains like Target, moving its products from a direct-to-consumer model to the mainstream shelves where millions of women shop.

By securing and heavily promoting these gynecologist recommendations, the company is building a formidable moat of credibility. It transforms its products from just another option in the wellness aisle into a clinically validated choice. This strategy directly addresses a major pain point revealed in its own research: that women feel underserved and are often navigating their health journey with little guidance. A doctor's endorsement acts as a powerful shortcut to trust.

This development signals a maturation of the women's health market, where the demand for choice is finally being met with products that are not only accessible but are also earning the confidence of the medical professionals who guide women's health decisions.